If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Dr. Gavin Robertson's research program focuses on malignant melanoma, the most deadly form of skin cancer. The central goal of his program is to unravel the biology and signaling pathways involved in melanoma tumor development in order to develop the next generation of therapeutic agents to treat this disease. Specifically, it involves identification and validation of novel therapeutic targets, discovery and development of new therapies and clinical evaluation of these drugs in patients.

Generally,the types of studies occurring the Robertson laboratory are:

Genetic and cell culture studies using animal and human models are used to identify and validate the involvement of candidate melanoma-causing genes. A recent example is the discovery of Akt3 involvement in approximately 70 percent of human melanomas.

Drug screens and medicinal chemistry are used to identify and develop new therapeutic agents. A recent example is the melanoma-treating drug ISC-4, which targets Akt3 signaling.

Nanotechnology and bioengineering are used to better deliver experimental agents into cancer cells. A recent example of this is the use of nanoliposomes and ultrasound that deliver therapeutic siRNA into melanoma cells.

Finally, agents are tested in the clinic for toxicity and tumor inhibitory efficacy. A recent example is a killed mycobacterium called CADI-5 that is being evaluated in clinical trials.

The ultimate goal of Dr. Robertson's translational research program is to develop better therapeutics for the treatment of melanoma based on the biology of the disease.

Fingerprint Dive into the research topics where Gavin Robertson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Tumor Suppressor Genes Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Apoptosis Medicine & Life Sciences
Mitogen-Activated Protein Kinases Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Tumors Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2006 2015

Chemoprevention
Small Interfering RNA
Melanoma
Phosphotransferases
Lymphatic System
Melanoma
Small Interfering RNA
Phosphotransferases
Therapeutics
Neoplasms
Melanoma
Therapeutics
Carcinogenesis
Quality of Life
Isothiocyanates
Chemoprevention
Melanoma
Selenium Compounds
Isothiocyanates
Skin Neoplasms
Chemoprevention
Melanoma
Small Interfering RNA
Skin
Technology

Research Output 1994 2019

2 Citations (Scopus)

Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

Bazewicz, C. G., Dinavahi, S. S., Schell, T. & Robertson, G., Jan 1 2019, In : Immunology. 156, 1, p. 47-55 9 p.

Research output: Contribution to journalReview article

Aldehyde Dehydrogenase
Regulatory T-Lymphocytes
Immunity
Neoplasms
Immune Tolerance
1 Citation (Scopus)

Loss of miR-155 upregulates WEE1 in metastatic melanoma

Disano, J. A., Huffnagle, I., Gowda, R., Spiegelman, V., Robertson, G. & Pameijer, C. R., Apr 1 2019, In : Melanoma Research. 29, 2, p. 216-219 4 p.

Research output: Contribution to journalArticle

Melanoma
Up-Regulation
Neoplasm Metastasis
MicroRNAs
Protein Kinases

PARI (PARPBP) suppresses replication stress-induced myeloid differentiation in leukemia cells

Nicolae, C., O’Connor, M. J., Schleicher, E. M., Song, C., Gowda, R., Robertson, G., Dovat, S. & Moldovan, G-L., Jul 4 2019, In : Oncogene. 38, 27, p. 5530-5540 11 p.

Research output: Contribution to journalArticle

Myeloid Leukemia
Leukemia
DNA Damage
Myeloid Cells
Differentiation Antigens

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity

Kokolus, K. M., Haley, J. S., Koubek, E. J., Gowda, R., Dinavahi, S. S., Sharma, A., Claxton, D., Helm, K., Drabick, J., Robertson, G., Neighbors, J., Hohl, R. & Schell, T., Feb 1 2019, In : OncoImmunology. 8, 2, e1539614.

Research output: Contribution to journalArticle

Biological Products
Immunity
Melanoma
Immunotherapy
Neoplasms

Correction to: eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis (Oncogene, (2016), 35, 49, (6293-6308), 10.1038/onc.2016.166)

Cheng, Y., Ren, X., Yuan, Y., Shan, Y., Li, L., Chen, X., Zhang, L., Takahashi, Y., Yang, J. W., Han, B., Liao, J. J., Li, Y., Harvey, H., Ryazanov, A., Robertson, G., Wan, G., Liu, D., Chen, A. F., Tao, Y. & Yang, J-M., Aug 16 2018, In : Oncogene. 37, 33, p. 4633-4634 2 p.

Research output: Contribution to journalComment/debate

Ficus
Tubulin
Oncogenes
Phosphotransferases